How many 8-K filings has Aytu Biopharma, Inc filed?

Aytu Biopharma, Inc (AYTU) has 12 8-K (Current Event Report) filings on record, spanning Jun 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Aytu Biopharma, Inc 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Aytu Biopharma, Inc 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Aytu Biopharma, Inc (AYTU) — 8-K Filings

All 8-K filings from Aytu Biopharma, Inc. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

8-K Filing — Dec 10, 2025
Aytu BioPharma Terminates Material Definitive Agreement — Aug 7, 2025 Risk: medium
On August 5, 2025, Aytu BioPharma, Inc. filed an 8-K to report the termination of a material definitive agreement. The filing does not specify the counterparty
Aytu BioPharma Enters Material Definitive Agreement — Jun 23, 2025 Risk: medium
On June 20, 2025, AYTU BIOPHARMA, INC. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as AYTU
8-K Filing — Jun 17, 2025
Aytu Biopharma Files 8-K Report — Jun 9, 2025 Risk: low
On June 9, 2025, Aytu Biopharma, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regula
Aytu BioPharma Acquires NovaLead Pharma Assets — Jun 6, 2025 Risk: medium
On June 5, 2025, Aytu BioPharma, Inc. announced the completion of its acquisition of certain assets from NovaLead Pharma, Inc. The transaction involved the acqu
Aytu BioPharma Files 8-K: Director Changes, Officer Updates — May 21, 2025 Risk: medium
On May 21, 2025, Aytu BioPharma, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, changes in its offi
Aytu BioPharma Files 8-K Report — Dec 4, 2024 Risk: low
On December 3, 2024, Aytu BioPharma, Inc. filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The fil
Aytu BioPharma Files 8-K with Corporate Updates — Oct 1, 2024 Risk: low
Aytu BioPharma, Inc. filed an 8-K on October 1, 2024, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compan
Aytu BioPharma Files 8-K with Corporate Updates — Aug 6, 2024 Risk: low
Aytu BioPharma, Inc. filed an 8-K on August 6, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compa
Aytu BioPharma Files 8-K on Security Holder Vote — Jun 26, 2024 Risk: medium
On June 26, 2024, AYTU BIOPHARMA, INC. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. No sp
Aytu BioPharma Files 8-K for Material Definitive Agreement — Jun 18, 2024 Risk: medium
On June 12, 2024, Aytu BioPharma, Inc. entered into a material definitive agreement related to its financial obligations. The company also made a Regulation FD

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX